A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2017
At a glance
- Drugs Daratumumab (Primary) ; Atezolizumab
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CALLISTO
- Sponsors Janssen Research & Development
- 09 Nov 2017 Planned End Date changed from 27 Feb 2019 to 16 Oct 2020.
- 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
- 17 Aug 2017 Planned End Date changed from 4 Jan 2019 to 27 Feb 2019.